Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Wiratech Europe


Genopole Campus 1 – Business Center – 5 rue Henri Desbruères
91030 EVRY CEDEX – FRANCE
Phone: +33 (0)1 60 87 14 92
Email: Sami.djoulah@wiratech.com

Sami DJOULAH: CEO
Wiratech Europe - Genopole's Company Wiratech Europe - Genopole's Company

#Therapeutics

  • Immunology
  • Biomarkers
  • Signatures
  • HLA
  • TCR BCR

Field of Activity


Wiratech Europe is a healthcare company that uses scientific knowledge of human variability and instrumental technologies to provide innovative tests, devices and services.

Wiratech is specialized in next generation sequencing (NGS) and has acquired expertise in immunogenetic analysis. The company has developed a human leukocyte antigen (HLA) NGS technology and transferred it to many medical labs in Europe and Asia.

Wiratech is at the forefront of T-cell (TCR) and B-cell receptor (BCR) NGS expertise as applied to cancers, autoimmune diseases and transplantations. It furthermore intends to extend its expertise to psychiatric disorders and TCR-HLA interaction regulation.
BACKGROUND
Wiratech Europe was created in 2010 by Sami Djoulah, a geneticist trained under the supervision of Nobel Prize laureate Professor Jean Dausset. Sami Djoulah is an avid bio-entrepreneur. He received a Best New Company award in 2011 and a Business Creation prize in 2012. His areas of interest are precision medicine and personalized diagnosis in transplantation and immunotherapy.

In France, Sami Djoulah helped draft the Genomic Medicine France 2025 plan. Furthermore, in 2016, thanks to a collaborative study with the greater Paris public hospital system (AP-HP), Wiratech was chosen by authorities from the EU and the Ile-de-France administrative region to receive a European Regional Development Fund (ERDF). Finally, several research programs are being developed jointly with the Medicen competitiveness cluster and other institutes.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY

  • Reagents and consumables for the HLA system and the T-cell and B-cell repertoire
  • Integrated (cassette), single-use, fully enclosed device for TCR NGS
  • HLA typing service, TCR and other immunoassay typing services

CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
Beyond its status as an ERDF recipient and its collaborations with AP-HP, the Medicen competitiveness cluster and other institutes, Wiratech is also active on the international front. The company is working on major translational research programs in China, particularly in the field of lung cancer in Wuhan. Sami Djoulah also co-chairs the TCR / HLA immune interaction study underway at Stanford University in California (USA), and is furthermore involved in a national program of genomic medicine in Algeria. Wiratech is also participating in an immunotherapy research program in Romania.

COLLABORATIONS SOUGHT

  • Partners with an NGS Illuminate Platform to enable an NGS service solution for HLA typing and TCR / BCR clonotyping
  • Venture capital to raise funds (1 to 10 million euros)
  • Further Information

    staff member
    Annual Turnover: €236,468 
    Strengths
    Expertise in immune adaptation and mastery of related technologies
    Innovation Assets
    Proof of concept of signature established in several pathologies
    Other Facts
    Clinical studies identifying a signature for good drug responders

Share
Genopole’s Companies

#Therapeutics


In same field

DeepTope - Genopole's company

Deeptope

– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies

Discover
Phagos - Genopole's Company

PHAGOS

At Phagos, we use bacteria’s natural predator, the bacteriophage, to overcome infectious diseases in aquaculture.

Discover
Theranovir - Genopole's Company

Theranovir

Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases

Discover
Vaccinopole - entreprise génopolitaine

Vaccinopole

Production of BCG vaccines and BCG-based cancer and inflammation treatments, preparation and distribution of fresh log-phase BCG cultures.

Discover
Synsight - Genopole's Company

Synsight

Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

Discover
Santen - Genopole's Company

Santen

Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.

Discover
Pymabs - Genopole's Company

Pymabs

R & D services in the field of transient expression of recombinant proteins in plants.

Discover
Pharnext - Genopole's company

Pharnext SA

Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).

Discover
Pharming - Genopole's company - Logo 2021

PHARMING

Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Discover
PEP-Therapy - Genopole's Company - logo 2021

PEP-Therapy

PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Discover
Genosafe - Genopole's Company

Genosafe

GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.

Discover
Généthon - Genopole's Laboratory

Généthon

Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.

Discover
Eukarÿs - Genopole's company

Eukarÿs

Synthetic gene therapy for the treatment of severe human liver diseases and tools for the bioproduction of recombinant proteins and viruses using the proprietary expression system C3P3.

Discover
Enterome - Genopole's company

Enterome

Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.

Discover
Logo Ab Science - Genopole's company

AB Science

Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.

Discover
View all >
With the support from